Skip to main content
Top
Published in: BMC Infectious Diseases 1/2024

Open Access 01-12-2024 | Cryotherapy | Research

Comparing the efficacy of fluconazole and cryotherapy Versus cryotherapy alone on treating cutaneous leishmaniasis: a triple-blind randomized clinical trial

Authors: Ahmad Reza Parhizkar, Mehdi Sharafi, Susan Mansuri, Maryam Hadibarhaghtalab, Sima Afrashteh, Hossein Fatemian, Mahsa Rostami Chijan

Published in: BMC Infectious Diseases | Issue 1/2024

Login to get access

Abstract

Objective

Cutaneous Leishmaniasis (CL) is one of the highly prevalent endemic diseases in the Middle East. The disease is a complex skin infection imposing a heavy burden on many developing countries. This study aimed to evaluate the impact of adding oral fluconazole to topical cryotherapy on the treatment efficacy and time to achieve complete recovery of CL lesions.

Method

This triple-blind randomized clinical trial included 52 participants with CL. Participants were allocated to receive either weekly cryotherapy with liquid nitrogen and oral fluconazole at a dose of 6 mg/kg daily at a maximum of 400 mg for 6 weeks as the interventional arm or weekly cryotherapy with liquid nitrogen plus the placebo for the same period of 6 weeks as the control arm.

Results

Fifty-two eligible participants enrolled the study, with a CL lesion count of 1 to 8 (mean 1.96), and served as the interventional (n = 28) and control (n = 24) arms. The trend of the mean surface area of the lesions was significantly decreasing in both arms (P < 0.001), with no statistically significant difference between arms (P = 0.133) or all assessed time point pairwise comparisons (P > 0.05). There was no significant difference between the treatment arms in terms of the end-point recovery status (P = 0.491) or the frequency of post-treatment secretion (P = 0.437). No adverse effect was observed.

Conclusion

Despite a slightly higher reduction in the lesion surface in the cryotherapy and fluconazole treatment arm, the addition of fluconazole did not provide statistically significant therapeutic value to cryotherapy in the treatment of CL. However, with adjustment for the initial lesion size, the efficacy of the regimen in the interventional arm was more pronounced, though it was still insignificant.
Literature
2.
go back to reference Killick KR. The biology and control of phlebotomine sandflies. Clin Dermatol. 1999;17:279–89.CrossRef Killick KR. The biology and control of phlebotomine sandflies. Clin Dermatol. 1999;17:279–89.CrossRef
3.
4.
go back to reference WHO. Control of the leishmaniases: report of a meeting of the WHO Expert Commitee on the control of Leishmaniases. World Health Organ Tech Rep Ser. 2010;949:0–186. WHO. Control of the leishmaniases: report of a meeting of the WHO Expert Commitee on the control of Leishmaniases. World Health Organ Tech Rep Ser. 2010;949:0–186.
5.
go back to reference Dinc R. New developments in the treatment of cutaneous leishmaniasis. Asian Pac J Trop Med. 2022;15(5):196–205.CrossRef Dinc R. New developments in the treatment of cutaneous leishmaniasis. Asian Pac J Trop Med. 2022;15(5):196–205.CrossRef
6.
7.
go back to reference Garza-Tovar TF, Sacriste-Hernández MI, Juárez-Durán ER, Arenas R. An overview of the treatment of cutaneous leishmaniasis. Fac Reviews. 2020;9. Garza-Tovar TF, Sacriste-Hernández MI, Juárez-Durán ER, Arenas R. An overview of the treatment of cutaneous leishmaniasis. Fac Reviews. 2020;9.
8.
go back to reference Parvizi MM, Handjani F, Moein M, Hatam G, Nimrouzi M, Hassanzadeh J, et al. Efficacy of cryotherapy plus topical Juniperus excelsa M. Bieb cream versus cryotherapy plus placebo in the treatment of Old World cutaneous leishmaniasis: a triple-blind randomized controlled clinical trial. PLoS Negl Trop Dis. 2017;11(10):e0005957.PubMedPubMedCentralCrossRef Parvizi MM, Handjani F, Moein M, Hatam G, Nimrouzi M, Hassanzadeh J, et al. Efficacy of cryotherapy plus topical Juniperus excelsa M. Bieb cream versus cryotherapy plus placebo in the treatment of Old World cutaneous leishmaniasis: a triple-blind randomized controlled clinical trial. PLoS Negl Trop Dis. 2017;11(10):e0005957.PubMedPubMedCentralCrossRef
9.
go back to reference Oliveira-Neto MP, Schubach A, Mattos M, Goncalves-Costa SC, Pirmez C. Treatment of American cutaneous leishmaniasis: a comparison between low dosage (5 mg/kg/day) and high dosage (20 mg/kg/day) antimony regimens. Pathol Biol (Paris). 1997;45(6):496–99.PubMed Oliveira-Neto MP, Schubach A, Mattos M, Goncalves-Costa SC, Pirmez C. Treatment of American cutaneous leishmaniasis: a comparison between low dosage (5 mg/kg/day) and high dosage (20 mg/kg/day) antimony regimens. Pathol Biol (Paris). 1997;45(6):496–99.PubMed
10.
go back to reference Marques SA, Merlotto MR, Ramos PM, Marques MEA. American tegumentary leishmaniasis: severe side effects of pentavalent antimonial in a patient with chronic renal failure. An Bras Dermatol. 2019;94:355–7.PubMedPubMedCentralCrossRef Marques SA, Merlotto MR, Ramos PM, Marques MEA. American tegumentary leishmaniasis: severe side effects of pentavalent antimonial in a patient with chronic renal failure. An Bras Dermatol. 2019;94:355–7.PubMedPubMedCentralCrossRef
11.
go back to reference Berbert T, de Mello T, Wolf Nassif P, Mota C, Silveira A, Duarte G et al. Pentavalent antimonials combined with other Therapeutic Alternatives for the treatment of cutaneous and mucocutaneous leishmaniasis: a systematic review. Dermatol Res Pract. 2018:9014726. Berbert T, de Mello T, Wolf Nassif P, Mota C, Silveira A, Duarte G et al. Pentavalent antimonials combined with other Therapeutic Alternatives for the treatment of cutaneous and mucocutaneous leishmaniasis: a systematic review. Dermatol Res Pract. 2018:9014726.
12.
go back to reference Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis. 1997;24(4):684–703.PubMedCrossRef Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis. 1997;24(4):684–703.PubMedCrossRef
13.
14.
go back to reference Sharafi M, Pezeshki B, Reisi A, Kalantari M, Naghizadeh MM, Dast Manesh S. Detection of cutaneous leishmaniasis by PCR in Fasa district in 2012. J Adv Biomedical Sci. 2013;3(3):266–70. Sharafi M, Pezeshki B, Reisi A, Kalantari M, Naghizadeh MM, Dast Manesh S. Detection of cutaneous leishmaniasis by PCR in Fasa district in 2012. J Adv Biomedical Sci. 2013;3(3):266–70.
15.
go back to reference Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med. 2002;346(12):891–5.PubMedCrossRef Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med. 2002;346(12):891–5.PubMedCrossRef
16.
go back to reference López-Carvajal L, Cardona-Arias JA, Zapata-Cardona MI, Sánchez-Giraldo V, Vélez ID. Efficacy of cryotherapy for the treatment of cutaneous leishmaniasis: meta-analyses of clinical trials. BMC Infect Dis. 2016;16(1):1–11.CrossRef López-Carvajal L, Cardona-Arias JA, Zapata-Cardona MI, Sánchez-Giraldo V, Vélez ID. Efficacy of cryotherapy for the treatment of cutaneous leishmaniasis: meta-analyses of clinical trials. BMC Infect Dis. 2016;16(1):1–11.CrossRef
17.
go back to reference Chakravarty J, Sundar S. Drug resistance in leishmaniasis. J Global Infect Dis. 2010;2(2):167.CrossRef Chakravarty J, Sundar S. Drug resistance in leishmaniasis. J Global Infect Dis. 2010;2(2):167.CrossRef
18.
go back to reference Francesconi VA, Francesconi F, Ramasawmy R, Romero GAS, Alecrim MGC. Failure of fluconazole in treating cutaneous leishmaniasis caused by Leishmania guyanensis in the Brazilian Amazon: an open, nonrandomized phase 2 trial. PLoS Negl Trop Dis. 2018;12(2):e0006225.PubMedPubMedCentralCrossRef Francesconi VA, Francesconi F, Ramasawmy R, Romero GAS, Alecrim MGC. Failure of fluconazole in treating cutaneous leishmaniasis caused by Leishmania guyanensis in the Brazilian Amazon: an open, nonrandomized phase 2 trial. PLoS Negl Trop Dis. 2018;12(2):e0006225.PubMedPubMedCentralCrossRef
19.
go back to reference Michelerio A, Barruscotti S, Bossi G, Brazzelli V. Pediatric Old World cutaneous leishmaniasis treated with oral fluconazole: a case series. Pediatr Dermatol. 2018;35(3):384–7.PubMedCrossRef Michelerio A, Barruscotti S, Bossi G, Brazzelli V. Pediatric Old World cutaneous leishmaniasis treated with oral fluconazole: a case series. Pediatr Dermatol. 2018;35(3):384–7.PubMedCrossRef
20.
go back to reference Machado PR, Ampuero J, Guimarães LH, Villasboas L, Rocha AT, Schriefer A, et al. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS Negl Trop Dis. 2010;4(12):e912.PubMedPubMedCentralCrossRef Machado PR, Ampuero J, Guimarães LH, Villasboas L, Rocha AT, Schriefer A, et al. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS Negl Trop Dis. 2010;4(12):e912.PubMedPubMedCentralCrossRef
21.
go back to reference Rafaa M, Ingen-Housz-Oro S, Méry L, Le Turdu F, Wendling J, editors. Traitement par fluconazole de la leishmaniose cutanée chez l’enfant. Annales de Dermatologie et de Vénéréologie; 2007. Rafaa M, Ingen-Housz-Oro S, Méry L, Le Turdu F, Wendling J, editors. Traitement par fluconazole de la leishmaniose cutanée chez l’enfant. Annales de Dermatologie et de Vénéréologie; 2007.
22.
go back to reference Laffitte E, Genton B, Panizzon R. Cutaneous leishmaniasis caused by Leishmania Tropica: treatment with oral fluconazole. Dermatology. 2005;210(3):249–51.PubMedCrossRef Laffitte E, Genton B, Panizzon R. Cutaneous leishmaniasis caused by Leishmania Tropica: treatment with oral fluconazole. Dermatology. 2005;210(3):249–51.PubMedCrossRef
23.
go back to reference Momeni A, Aminjavaheri M, Omidghaemi M. Treatment of cutaneous leishmaniasis with ketoconazole cream. J Dermatological Treat. 2003;14(1):26–9.CrossRef Momeni A, Aminjavaheri M, Omidghaemi M. Treatment of cutaneous leishmaniasis with ketoconazole cream. J Dermatological Treat. 2003;14(1):26–9.CrossRef
24.
go back to reference Larbi EB, Al-Khawajah A, Al-Gindan Y, Jain S, Abahusain A, Al-Zayer A. A randomized, double-blind, clinical trial of topical clotrimazole versus miconazole for treatment of cutaneous leishmaniasis in the eastern province of Saudi Arabia. Am J Trop Med Hyg. 1995;52(2):166–8.PubMedCrossRef Larbi EB, Al-Khawajah A, Al-Gindan Y, Jain S, Abahusain A, Al-Zayer A. A randomized, double-blind, clinical trial of topical clotrimazole versus miconazole for treatment of cutaneous leishmaniasis in the eastern province of Saudi Arabia. Am J Trop Med Hyg. 1995;52(2):166–8.PubMedCrossRef
25.
go back to reference Galvao EL, Rabello A, Cota GF. Efficacy of azole therapy for tegumentary leishmaniasis: a systematic review and meta-analysis. PLoS ONE. 2017;12(10):e0186117.PubMedPubMedCentralCrossRef Galvao EL, Rabello A, Cota GF. Efficacy of azole therapy for tegumentary leishmaniasis: a systematic review and meta-analysis. PLoS ONE. 2017;12(10):e0186117.PubMedPubMedCentralCrossRef
26.
go back to reference Mussi SV, Fernandes AP, Ferreira LAM. Comparative study of the efficacy of formulations containing fluconazole or paromomycin for topical treatment of infections by Leishmania (Leishmania) major and Leishmania (Leishmania) amazonensis. Parasitol Res. 2007;100(6):1221–6.PubMedCrossRef Mussi SV, Fernandes AP, Ferreira LAM. Comparative study of the efficacy of formulations containing fluconazole or paromomycin for topical treatment of infections by Leishmania (Leishmania) major and Leishmania (Leishmania) amazonensis. Parasitol Res. 2007;100(6):1221–6.PubMedCrossRef
27.
go back to reference Beach DH, Goad LJ, Holz GG Jr. Effects of antimycotic azoles on growth and sterol biosynthesis of Leishmania promastigotes. Mol Biochem Parasitol. 1988;31(2):149–62.PubMedCrossRef Beach DH, Goad LJ, Holz GG Jr. Effects of antimycotic azoles on growth and sterol biosynthesis of Leishmania promastigotes. Mol Biochem Parasitol. 1988;31(2):149–62.PubMedCrossRef
28.
go back to reference Emad M, Hayati F, Fallahzadeh MK, Namazi MR. Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: a randomized clinical trial. J Am Acad Dermatol. 2011;64(3):606–8.PubMedCrossRef Emad M, Hayati F, Fallahzadeh MK, Namazi MR. Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: a randomized clinical trial. J Am Acad Dermatol. 2011;64(3):606–8.PubMedCrossRef
29.
go back to reference Sklavos AV, Walls T, Webber MT, Watson AB. Cutaneous leishmaniasis in a child treated with oral fluconazole. Australas J Dermatol. 2010;51(3):195–7.PubMedCrossRef Sklavos AV, Walls T, Webber MT, Watson AB. Cutaneous leishmaniasis in a child treated with oral fluconazole. Australas J Dermatol. 2010;51(3):195–7.PubMedCrossRef
30.
go back to reference White J, Salisbury J, Jones J, Higgins E, Vega-Lopez F. Cutaneous leishmaniasis: three children with Leishmania major successfully treated with itraconazole. Pediatr Dermatol. 2006;23(1):78–80.PubMedCrossRef White J, Salisbury J, Jones J, Higgins E, Vega-Lopez F. Cutaneous leishmaniasis: three children with Leishmania major successfully treated with itraconazole. Pediatr Dermatol. 2006;23(1):78–80.PubMedCrossRef
31.
go back to reference Morizot G, Delgiudice P, Caumes E, Laffitte E, Marty P, Dupuy A, et al. Healing of Old World cutaneous leishmaniasis in travelers treated with fluconazole: drug effect or spontaneous evolution? Am J Trop Med Hyg. 2007;76(1):48–52.PubMedCrossRef Morizot G, Delgiudice P, Caumes E, Laffitte E, Marty P, Dupuy A, et al. Healing of Old World cutaneous leishmaniasis in travelers treated with fluconazole: drug effect or spontaneous evolution? Am J Trop Med Hyg. 2007;76(1):48–52.PubMedCrossRef
32.
go back to reference Sundar S, Singh VP, Agrawal NK, Gibbs DL, Murray HW. Treatment of kala-azar with oral fluconazole. Lancet. 1996;348(9027):614.PubMedCrossRef Sundar S, Singh VP, Agrawal NK, Gibbs DL, Murray HW. Treatment of kala-azar with oral fluconazole. Lancet. 1996;348(9027):614.PubMedCrossRef
33.
go back to reference Sousa AQ, Frutuoso MS, Moraes EA, Pearson RD, Pompeu MM. High-dose oral fluconazole therapy effective for cutaneous leishmaniasis due to Leishmania (Vianna) braziliensis. Clin Infect Dis. 2011;53(7):693–5.PubMedCrossRef Sousa AQ, Frutuoso MS, Moraes EA, Pearson RD, Pompeu MM. High-dose oral fluconazole therapy effective for cutaneous leishmaniasis due to Leishmania (Vianna) braziliensis. Clin Infect Dis. 2011;53(7):693–5.PubMedCrossRef
34.
go back to reference Prates FVO, Dourado ME, Silva SC, Schriefer A, Guimarães LH, Brito MGO et al. Fluconazole in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis: a randomized controlled trial. Clin Infect Dis 2016:ciw662. Prates FVO, Dourado ME, Silva SC, Schriefer A, Guimarães LH, Brito MGO et al. Fluconazole in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis: a randomized controlled trial. Clin Infect Dis 2016:ciw662.
35.
go back to reference Farajzadeh S, Esfandiarpour I, Haghdoost AA, Mohammadi S, Mohebbi A, Mohebbi E, et al. Comparison between combination therapy of oral terbinafine and cryotherapy versus systemic meglumine antimoniate and cryotherapy in cutaneous leishmaniasis: a randomized clinical trial. Iran J Parasitol. 2015;10(1):1.PubMedPubMedCentral Farajzadeh S, Esfandiarpour I, Haghdoost AA, Mohammadi S, Mohebbi A, Mohebbi E, et al. Comparison between combination therapy of oral terbinafine and cryotherapy versus systemic meglumine antimoniate and cryotherapy in cutaneous leishmaniasis: a randomized clinical trial. Iran J Parasitol. 2015;10(1):1.PubMedPubMedCentral
36.
go back to reference Asilian A, Sadeghinia A, Faghihi G, Momeni A. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime®) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime®) alone for the treatment of cutaneous leishmaniasis. Int J Dermatol. 2004;43(4):281–3.PubMedCrossRef Asilian A, Sadeghinia A, Faghihi G, Momeni A. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime®) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime®) alone for the treatment of cutaneous leishmaniasis. Int J Dermatol. 2004;43(4):281–3.PubMedCrossRef
37.
go back to reference Jowkar F, Dehghani F, Jamshidzadeh A. Is topical nitric oxide and cryotherapy more effective than cryotherapy in the treatment of old world cutaneous leishmaniasis? J Dermatological Treat. 2012;23(2):131–5.CrossRef Jowkar F, Dehghani F, Jamshidzadeh A. Is topical nitric oxide and cryotherapy more effective than cryotherapy in the treatment of old world cutaneous leishmaniasis? J Dermatological Treat. 2012;23(2):131–5.CrossRef
38.
go back to reference Fekri A, Rahnama Z, Khalili M, Pardakhti Dookhani A, Khazaeli P, Bahaadin Beigi K. The efficacy of co-administration of topical niosomal dapsone gel and intralesional injection of glucantime in cutaneous leishmaniasis in comparison with cryotherapy plus intralesional injection of glucantime. J Kerman Univ Med Sci. 2015;22(2):117–32. Fekri A, Rahnama Z, Khalili M, Pardakhti Dookhani A, Khazaeli P, Bahaadin Beigi K. The efficacy of co-administration of topical niosomal dapsone gel and intralesional injection of glucantime in cutaneous leishmaniasis in comparison with cryotherapy plus intralesional injection of glucantime. J Kerman Univ Med Sci. 2015;22(2):117–32.
Metadata
Title
Comparing the efficacy of fluconazole and cryotherapy Versus cryotherapy alone on treating cutaneous leishmaniasis: a triple-blind randomized clinical trial
Authors
Ahmad Reza Parhizkar
Mehdi Sharafi
Susan Mansuri
Maryam Hadibarhaghtalab
Sima Afrashteh
Hossein Fatemian
Mahsa Rostami Chijan
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2024
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-024-09211-5

Other articles of this Issue 1/2024

BMC Infectious Diseases 1/2024 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.